От хорошего к великому

151 
Интервью в рамках исследования #2-C, c. 16.

---

152 
“Man of Steel: Correnti Hopes to Take Nucor to No. 1”, 
The Business
Journal-Charlotte,
September 19, 1994, 3.

---

153 
Standard & Poor’s Industry Survey Database, Metals: Industrial, Iron and
Steel, January 18, 2001, Leo J. Larkin, Metals Analyst.

---

154 
Интервью в рамках исследования #7-C, с. 13.

---

155 
Интервью в рамках исследования #7-E, с. 7; Jeffrey L. Rodengen, 
The
Legend of Nucor
(Write Stuff, 1997), 45.

---

156 
Jeffrey L. Rodengen, 
The Legend of Nucor
(Write Stuff, 1997), 39.

---

157 
Интервью в рамках исследования #7-A, с. 3.

---

158 
Joseph F. Cullman 3rd, 
I’m a Lucky Guy
(Joseph F. Cullman 3rd, 1998),
144; Richard Kluger, 
Ashes to Ashes
(Alfred A. Knopf: New York, 1996), 485;
“Beverage management: risky – but straight up 7Up”, 
Forbes,
April 12, 1982,
208; “Coke Peppers 7Up and Pepsi”, 
Advertising Age,
February 24, 1986, 2, 86.

---

159 
Joseph F. Cullman 3rd, 
I’m a Lucky Guy
(Joseph F. Cullman 3rd, 1998),
147.

---

160 
John Strohmeyer, 
Crisis in Bethlehem
(Pittsburgh: University of Pittsburgh
Press, 1986), 72–73; “The labors of Trautlein”, 
Forbes,
February 15, 1981, 36;
“Bethlehem’s Thin Slab Yawn”, 
American Metal Market,
November 17, 1989, 4;
“Bethlehem Museum”, 
National Public Radio Transcript,
July 5, 1998.

---

161 
“Upjohn: Safety of Upjohn’s Oral Antidiabetic Drug Doubted in Study;
Firm Disputes Finding”, 
The Wall Street Journal,
May 21, 1970, 6; “Upjohn: A
bitter pill for Upjohn shareholders (Drug company involved in antibiotic
controversy)”, 
Financial World,
January 23, 1974, 28; “Upjohn: The Upjohn
Company: Presentation by R.T. Parfet, Jr., Chairman of the Board and Chief
Executive Officer, and L.C. Hoff, Vice President and General Manager,
Pharmaceutical Division, to the Security Analysts of San Francisco, September
11, 1975”, 
The Wall Street Transcript,
October 13, 1975, 41648–41650;
“Upjohn: Hair-Raising Happenings at Upjohn (Testing a cure for baldness, the
company squirms at the unwelcome clamor)”, 
Fortune,
April 6, 1981, 67–69;
“Upjohn: FDA Says Upjohn Exaggerated Claims On Drug’s Value in Treating
Baldness”, 
The Wall Street Journal,
June 18, 1986, 6; “Upjohn: Rip Tide: Can
Upjohn manage its way out of a product gap? If not, it could be swept into the
industry merger wave”, 
Financial World,
September 5, 1989, 26–28; “Upjohn:
The Corporation: Strategies: Will This Formula Cure What Ails Upjohn: As the
sharks circle, it’s spending big on R&D and marketing”, 
Business Week,
September 18, 1989, 65; “Upjohn: Technology & Medicine: Upjohn Sleep Drug
Being Investigated For Safety by FDA”, 
The Wall Street Journal,
September 20,
1984, B4; “Upjohn: Medicine: Halcion Takes Another Hit: Tainted data played a
key role in FDA approval”, 
Newsweek,
February 17, 1992, 58; “Upjohn:
Medicine: Fueling the Fire Over Halcion: Upjohn’s own staff has raised safety
concerns”, 
Newsweek,
May 25, 1992, 84; “Upjohn: Top of the News:
Successions: At Upjohn, A Grim Changing of the Guard: Ley Smith inherits the
problem-plagued drugmaker at a critical juncture”, 
Business Week,
May 3, 1993,
36.

---